Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3971596 | 0.99 | HRH3 (0.62) | HRH3KCNH2HTR3AHRH4IRAK4 | |
| SCHEMBL13648850 | 0.86 | HRH3 (0.63) | HRH3KCNH2HRH4 | |
| Hydrochloric Acid SCHEMBL3969987 | 0.85 | HRH3 (0.61) | HRH3KCNH2HRH4 | |
| SCHEMBL13648781 | 0.81 | HRH3 (0.59) | HRH3KCNH2HTR3AHRH4 | |
| Hydrochloric Acid SCHEMBL3970898 | 0.80 | HRH3 (0.58) | HRH3KCNH2HTR3AHRH4 | |
| SCHEMBL13648840 | 0.78 | HRH3 (0.72) | HRH3HTR3AHRH4 | |
| SCHEMBL13648774 | 0.78 | HRH3 (1.00) | HRH3HTR3AHRH4 | |
| SCHEMBL13648776 | 0.77 | HRH3 (1.00) | HRH3HTR3AHRH4 | |
| SCHEMBL13648829 | 0.77 | HRH3 (0.66) | HRH3HTR3AHRH4 | |
| Hydrochloric Acid SCHEMBL3973403 | 0.76 | HRH3 (0.70) | HRH3HTR3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| EP-1446386-A1 | BENZIMIDAZOL- OR INDOL-AMINOACETONITRILE DERIVATIVES FOR PARASITE CONTROL | Novartis AG (CH) | 2004-08-18 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003042184-A1 | BENZIMIDAZOL- OR INDOL-AMINOACETONITRILE DERIVATIVES FOR PARASITE CONTROL | NOVARTIS AG (CH) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | HRH3 1/4885KCNH2 637/4885HTR3A 38/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | HRH3 1/4885KCNH2 637/4885HTR3A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.